LEADER 07195nam 2202149z- 450 001 9910557129103321 005 20240124162354.0 035 $a(CKB)5400000000040763 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/68429 035 $a(EXLCZ)995400000000040763 100 $a20202105d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aAnticancer Agents$eDesign, Synthesis and Evaluation 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 electronic resource (606 p.) 311 $a3-0365-0140-1 311 $a3-0365-0141-X 330 $aThis book is a printed edition of the Special Issue entitled ?Anticancer Agents: Design, Synthesis and Evaluation? that was published in Molecules. Two review articles and thirty research papers are included in the Special Issue. Three second-generation androgen receptor antagonists that have been approved by the U.S. FDA for the treatment of prostate cancer have been reviewed. Identification of mimics of protein partners as protein-protein interaction inhibitors via virtual screening has been summarized and discussed. Anticancer agents targeting various protein targets, including IGF-1R, Src, protein kinase, aromatase, HDAC, PARP, Toll-Like receptor, c-Met, PI3Kdelta, topoisomerase II, p53, and indoleamine 2,3-dioxygenase, have been explored. The analogs of three well-known tubulin-interacting natural products, paclitaxel, zampanolide, and colchicine, have been designed, synthesized, and evaluated. Several anticancer agents representing diverse chemical scaffolds were assessed in different kinds of cancer cell models. The capability of some anticancer agents to overcome the resistance to currently available drugs was also studied. In addition to looking into the in vitro ability of the anticancer agents to inhibit cancer cell proliferation, apoptosis, and cell cycle, in vivo antitumor efficacy in animal models and DFT were also investigated in some papers. 517 $aAnticancer Agents 606 $aMedicine$2bicssc 610 $abenzofurans 610 $achemical synthesis 610 $acytotoxic properties 610 $aHeLa 610 $aMOLT-4 610 $aK562 610 $aanticancer 610 $aanti-neuroinflammation 610 $acoumarin 610 $adihydroartemisinin 610 $aflavonoids 610 $aallene 610 $aE-stereoselective 610 $aregioselective 610 $aanti-cancer activity 610 $acyanopyridone 610 $asubstituted pyridine 610 $apyridotriazine 610 $apyrazolopyridine 610 $athioxotriazopyridine 610 $aanticancer activity 610 $aHepG2 610 $aantitumor activity 610 $acomputational docking 610 $aMDM2-p53 interaction 610 $axanthones 610 $ayeast-based assays 610 $aestrone derivatives 610 $ahydrazine 610 $aN-substituted pyrazoline 610 $aanti-ovarian cancer 610 $atopoisomerase II inhibitor 610 $akinase inhibitor 610 $aantiproliferative agent 610 $aurea 610 $asynthesis 610 $aantiproliferative activity 610 $aapoptosis 610 $aindoleamine 2,3-dioxygenase 610 $ainhibitor 610 $aanti-tumor 610 $aimmune modulation 610 $atryptophan metabolism 610 $ataxoids 610 $a?III-tubulin 610 $aP-glycoprotein 610 $adrug resistance 610 $athiopene 610 $athienopyrimidinone 610 $athiazolidinone 610 $abreast cancer 610 $abenzofuran?pyrazole 610 $ananoparticles 610 $acytotoxic activity 610 $aPARP-1 inhibition 610 $a3,6-dibromocarbazole 610 $a5-bromoindole 610 $acarbazole 610 $aactin 610 $amigration 610 $aThienopyrimidine 610 $aPyrazole 610 $aPI3K? inhibitor 610 $aquinazolin-4(3H)-one 610 $aquinazolin-4(3H)-thione 610 $aSchiff base 610 $aantioxidant activity 610 $aDFT study 610 $aortho-quinones 610 $abeta-lapachone 610 $atanshione IIA 610 $aPI3Ks 610 $aPI3K? inhibitors 610 $a2H-benzo[e][1,2,4]thiadiazine 1,1-dioxide 610 $aanticancer agents 610 $aprotein?protein interactions 610 $avirtual screening 610 $amimetics 610 $adrug discovery 610 $abivalency 610 $apolyvalency 610 $aantitumor 610 $acell cycle 610 $aovarian cancer 610 $aP-MAPA 610 $aIL-12 610 $aTLR signaling 610 $ainflammation 610 $achemoresistance 610 $a4-(pyridin-4-yloxy)benzamide 610 $a1,2,3-triazole 610 $ac-Met 610 $anatural product 610 $aanticancer agent 610 $azampanolide 610 $aTalazoparib 610 $aPARP inhibitor 610 $aprodrug 610 $ao-nitro-benzyl 610 $aphotoactivatable protecting groups 610 $asalinomycin 610 $aovercoming drug resistance 610 $atumor specificity 610 $asynergy 610 $a5-fluorouracil 610 $agemcitabine 610 $aamides/esters 610 $acolchicine analogs 610 $athiocolchicine 610 $acolchiceine 610 $aantimitotic agents 610 $ahydrates 610 $adihydropyranoindole 610 $aHDAC inhibitors 610 $aneuroblastoma 610 $aaromatase 610 $aMCF-7 610 $aNIH3T3 610 $abenzimidazole 610 $atriazolothiadiazine 610 $adocking 610 $aADME 610 $aorganosilicon compounds 610 $aSILA-409 (Alis-409) 610 $aSILA-421 (Alis-421) 610 $amultidrug resistance (MDR) reversal 610 $aABCB1 (P-glycoprotein) 610 $acolon cancer 610 $acolchicine amide 610 $acolchicine sulfonamide 610 $atubulin inhibitors 610 $adocking studies 610 $acrystal structure 610 $aPROTACs 610 $aprotein degradation 610 $aIGF-1R 610 $aSrc 610 $aprotein kinase 610 $aphenylpyrazolopyrimidine 610 $aenzyme inhibition 610 $amolecular simulation 610 $aandrogen receptor 610 $aprostate cancer 610 $aenzalutamide 610 $aapalutamide 610 $adarolutamide 610 $atriple-negative breast cancer 610 $acytotoxicity 610 $achrysin analogues 610 $aflavonoid 610 $aanticancer compounds 615 7$aMedicine 700 $aChen$b Qiao-Hong$4edt$01313308 702 $aChen$b Qiao-Hong$4oth 906 $aBOOK 912 $a9910557129103321 996 $aAnticancer Agents$93031264 997 $aUNINA